The US Department of Health and Human Services (HHS) has committed to buying large volumes of a smallpox vaccine called ACAM2000 as part of its preparedness efforts against biodefense threats.
The HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), which oversees the Strategic National Stockpile (SNS), will award approximately $170 million to Emergent BioSolutions (NYSE: EBS), for the purchase this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze